CSG GD2Alternative Names: CSG-GD2
Latest Information Update: 09 Aug 2016
At a glance
- Originator CARsgen
- Class CAR-T cell therapies
- Mechanism of Action T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuroblastoma
Most Recent Events
- 09 Aug 2016 Preclinical trials in Neuroblastoma in China (Parenteral)